| target_id,question,ground_truth_summary |
| NCT00726128,, |
| NCT01417065,, |
| NCT00445900,, |
| NCT05827471,,This clinical study aims to evaluate QSOX1 as a biomarker for colon cancer. Patients must have pathologically confirmed colon cancer and not have received any local or systemic treatment prior to surgery. The study requires complete clinical data for inclusion. |
| NCT06324344,, |
| NCT03769532,, |
| NCT00310063,What are the eligibility criteria for young cancer patients receiving chemotherapy to participate in a study evaluating acupressure for preventing nausea and vomiting?,This study evaluates acupressure in preventing nausea and vomiting in young cancer patients receiving chemotherapy. Patients must be receiving in-patient primary oncology care at Brenner Children's Hospital and be on specific chemotherapy agents like alkylating agents or high-dose cytarabine. The primary objective is to assess the effectiveness of acupressure as a supportive care intervention. |
| NCT03827993,What are the inclusion criteria for women with gynecologic cancer to participate in a study aimed at improving sexual health?,"This study aims to improve sexual health in gynecologic cancer patients. Eligible participants must be able to consent, screen positive for sexual health dysfunction, and have a diagnosis of any gynecologic malignancy. Patients may have received prior treatment including surgery, chemotherapy, or radiation." |
| NCT03410121,"For adult patients with advanced or metastatic solid tumors requiring intravenous chemotherapy, what are the eligibility criteria for a study comparing humeral versus thoracic implantation of an implantable venous access device?",This study compares humeral or thoracic implantation of an implantable venous access device in adult patients with advanced or metastatic solid tumors requiring intravenous chemotherapy. Participants must be over 18 years old and provide signed consent. Exclusion criteria include a life expectancy less than 12 months or abnormal coagulation. |
| NCT06605404,"What are the general and cohort-specific eligibility criteria for patients with malignant solid tumors to participate in a pan-tumor MRD study, particularly regarding their disease stage and treatment intent?","This pan-tumor MRD study aims to identify novel therapeutic targets and study the tumor microenvironment in various solid tumors. Eligible patients must be 18 or older with a histologically confirmed malignant solid tumor, eligible for curative intent therapy with planned surgical resection. Cohort-specific criteria apply, for example, Stage II or operable III cancer for bladder urothelial carcinoma and melanoma." |
| NCT03623152,What are the inclusion criteria for patients undergoing colonoscopy to participate in a study investigating colorectal neoplasia and microbiota?,"This study investigates colorectal neoplasia and microbiota, focusing on whether differences exist between left and right-sided lesions. Participants must be over 18 years old and have an indication for a scheduled colonoscopy, either for symptom investigation, CRC screening, or endoscopic procedures for known adenoma/CRC. Patients on antibiotics, prebiotics, or probiotics within the last month are excluded." |
| NCT07371247,"For patients with locally advanced esophageal squamous cell carcinoma (ESCC) who are candidates for definitive chemoradiotherapy, what are the key inclusion criteria for a study on ctDNA-MRD guided adjuvant treatment escalation?","This study evaluates the safety and efficacy of ctDNA-MRD guided adjuvant treatment escalation after definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Eligible patients must have histologically confirmed ESCC, clinical stage II-IV unresectable disease, and no prior systemic therapy. They must be planned to receive definitive chemoradiotherapy." |
| NCT02848638,What are the specific criteria for hepatocellular carcinoma (HCC) patients to be included in a study using Pair Production PET Imaging to detect particle distribution during Yttrium-90 Radioembolization?,This study uses Pair Production PET Imaging to detect particle distribution in UWMC patients undergoing Yttrium-90 Radioembolization for hepatocellular carcinoma (HCC). Eligible patients must be over 18 years old and have HCC greater than 5 cm or tumor-associated portal vein thrombosis. The study aims to evaluate the imaging technique during this treatment. |
| NCT00424255,What are the specific pathological staging and high-risk factor requirements for patients with squamous cell carcinoma of the head and neck (SCCHN) to be eligible for an adjuvant Lapatinib study after surgery?,"This study investigates adjuvant Lapatinib in high-risk head and neck cancer subjects after surgery. Patients must have histologically confirmed SCCHN of specific sites, pathological Stage II, III or IVa with no gross residual disease, and at least one high-risk factor like extracapsular extension or positive resection margins. Surgery must be completed within 4-6 weeks prior to randomization." |
| NCT07368478,"What are the general and cohort-specific eligibility criteria for patients with advanced solid malignancies to participate in a Phase 1a/1b study of BC2027, particularly regarding GPC3 expression and prior treatment history for NSCLC or HCC?","This Phase 1a/1b study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of BC2027 in patients with advanced solid malignancies. General eligibility includes ECOG PS 0-1 and life expectancy ≥ 3 months. For Phase 1a, tumors must express GPC3. For Phase 1b, specific cohorts like NSCLC and HCC require GPC3 positivity and defined prior systemic therapies." |
| NCT04656678,What are the specific diagnostic and imaging criteria for patients with intermediate-risk prostate cancer to be eligible for focal US-guided cryo-ablation using DynaCAD/UroNAV preplanning/guidance?,"This study evaluates focal US-guided cryo-ablation using DynaCAD/UroNAV preplanning/guidance for intermediate-risk prostate cancer. Eligible participants must have histologically confirmed organ-confined clinical T1C or T2a prostate cancer, visualized on MR imaging, with a Gleason Score ≤ 7. Patients with very low-risk prostate cancer are excluded." |
| NCT04740385,What are the inclusion criteria for patients undergoing thoracic surgeries to participate in a study evaluating the role of lung ultrasound for confirming correct double lumen endotracheal tube placement?,"This study evaluates the role of lung ultrasound in confirming correct double lumen endotracheal tube placement during thoracic surgeries. Eligible participants are patients scheduled for general anesthesia requiring double lumen endotracheal intubation, classified as ASA I-II. The study aims to assess the diagnostic accuracy of lung ultrasound." |
| NCT00064298,"For patients with curatively treated squamous cell carcinoma of the upper aerodigestive tract, what are the eligibility criteria for a study investigating fruit and vegetable extracts, particularly regarding their disease-free interval and prior malignancies?","This study investigates fruit and vegetable extracts in patients with curatively treated stage I-IV squamous cell carcinoma of the upper aerodigestive tract. Patients must be disease-free for at least 6 months and no more than 3 years after completion of standard therapy. Exclusion criteria include other malignancies within the past 5 years, except for nonmelanoma skin cancer or carcinoma in situ of the cervix." |
| NCT07386587,What are the age and disease-specific inclusion criteria for pediatric patients with Juvenile Idiopathic Arthritis (JIA) to participate in a study comparing Methotrexate alone versus Methotrexate plus Etanercept?,This study compares Methotrexate alone versus Methotrexate + Etanercept for minimal/low disease activity in Juvenile Idiopathic Arthritis (JIA). Eligible participants are newly diagnosed polyarticular JIA patients aged 2-16 years. Patients with other types of JIA or a history of malignancy are excluded. |
| NCT05145816,What are the specific prior treatment and disease measurability requirements for patients with relapsed or refractory AL amyloidosis to be eligible for a Phase 1/2a study of Belantamab Mafodotin?,"This Phase 1/2a study evaluates Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis. Eligible participants must have received one or more prior lines of treatment, including a proteasome inhibitor, alkylator, and anti-CD38 antibody, and/or autologous stem cell transplant. Patients must also have measurable disease and adequate organ function." |
| NCT05353504,What are the primary anthropometric and general health inclusion criteria for individuals to participate in a study on the impact of microbiome-changing interventions on food decision-making in overweight and obese populations?,"This study investigates the impact of microbiome-changing interventions on food decision-making in individuals with overweight and obesity. Participants must have a BMI ≥ 25 kg/m2 or specific waist-to-hip ratio criteria. Exclusion criteria include clinically relevant psychiatric disease, chronic inflammatory or malignant disease, and pregnancy." |
| NCT02955758,What are the specific prior treatment and biomarker requirements for patients with recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC) to be eligible for a study of Pembrolizumab?,"This study investigates Pembrolizumab in patients with recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). Eligible patients must have received at least one prior line of systemic therapy, or be treatment-naive with a tumor proportion score (TPS) ≥ 50% and no EGFR mutation or ALK rearrangement. Patients with stable, treated brain metastases are allowed." |
| NCT01342978,What are the age and disease-specific inclusion criteria for patients with oropharyngeal cancer to participate in a study on Human Papillomavirus (HPV) oral transmission?,"This study investigates Human Papillomavirus (HPV) oral transmission in partners over time, focusing on patients with oropharyngeal cancer. Eligible participants must be 18 years or older with incident oropharyngeal cancer. Patients with a history of organ transplant, autoimmune disorder treated with steroids, lymphoma, leukemia, or bone marrow transplant are excluded." |
| NCT04722692,What are the specific preoperative diagnostic and surgical planning criteria for women with ductal carcinoma in situ (DCIS) or other pre-invasive lesions to be eligible for a study on delayed sentinel lymph node biopsy?,"This study investigates delayed sentinel lymph node biopsy in ductal carcinoma in situ (DCIS). Eligible patients include those with a preoperative diagnosis of DCIS planned for mastectomy, or those undergoing risk-reducing mastectomy. Specific criteria also cover suspicious pre-invasive or unclear lesions where upfront SLND would typically be considered." |
| NCT06999798,"For patients with breast cancer and biopsy-proven axillary lymph node involvement, what are the key inclusion criteria for a study evaluating an optimized ultrasound twinkling marker for lymph node imaging?","The UTMOST2 Trial evaluates an optimized ultrasound twinkling marker for imaging lymph nodes in patients with clinically node-positive breast cancer. Eligible participants must be 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node. Surgical management, including preoperative Iodine-125 seed localization, will be determined by the surgeon." |
| NCT05064852,What are the key eligibility criteria for patients with unresectable or metastatic biliary tract carcinoma to participate in a real-world study evaluating the safety and efficacy of Surufatinib?,"This real-world study evaluates the safety and efficacy of Surufatinib in patients with unresectable or metastatic biliary tract carcinoma (BTC). Eligible participants must be aged 18 or older, have histologically or cytologically confirmed BTC, an ECOG score of 0-2, and measurable lesions. Patients with contraindications to Surufatinib or other active malignancies within 5 years are excluded." |
| NCT06806930,"For women with early-stage breast cancer, what are the specific hormone receptor and HER2 status requirements to be eligible for a Phase II study predicting response to neoadjuvant endocrine therapy (Neo-PREDICT)?","The Neo-PREDICT Phase II study aims to predict response to neoadjuvant endocrine therapy (NET) in patients with breast cancer. Eligible participants must have histologically or cytologically confirmed invasive breast carcinoma, clinical stage 1-3, and be candidates for surgical resection. Crucially, tumors must be Estrogen Receptor > 10% positive and HER2 negative or HER2 low." |
| NCT07257471,What are the specific tumor characteristics and prior treatment considerations for non-small cell lung cancer (NSCLC) patients to be eligible for a study on methylation markers in early-stage lung cancer treated with co-ablation system therapy?,"This study focuses on the application of methylation markers in early-stage non-small cell lung cancer (NSCLC) patients treated with co-ablation system therapy. Eligible patients must have histopathologically/clinically diagnosed NSCLC, be deemed unsuitable for or refuse surgical resection, and have specific tumor size and location criteria (e.g., max diameter ≤ 5 cm for peripheral tumors). Patients with a history of other malignant tumors or autoimmune diseases are excluded." |
| NCT01111604,"For patients with metastatic colorectal cancer who have progressed on an irinotecan-based first-line chemotherapy regimen, what are the key eligibility criteria for a study evaluating Ramucirumab or Icrucumab?",This study evaluates Ramucirumab or Icrucumab in patients with metastatic colorectal cancer. Eligible participants must have experienced disease progression on an irinotecan-based first-line chemotherapy regimen. Key exclusion criteria include prior oxaliplatin-based chemotherapy for metastatic CRC (unless adjuvant and >12 months prior) and documented brain or leptomeningeal metastases. |
| NCT00602667,What are the specific histological diagnoses and age criteria for young children with newly diagnosed CNS tumors to be eligible for a risk-adapted therapy study?,"This study investigates risk-adapted therapy for young children with embryonal brain tumors, choroid plexus carcinoma, high-grade glioma, or ependymoma. Eligible patients must have histologically confirmed newly diagnosed CNS tumors and be under 3 years of age at diagnosis, with specific exceptions for medulloblastoma patients aged 3 to <5 years. Patients are stratified into low, intermediate, and high-risk groups based on histological and metastatic status." |
| NCT04743999,What are the specific staging and treatment candidacy requirements for women with endometrial carcinoma to be eligible for a study evaluating outcomes of multimodality treatment?,"This study evaluates outcomes in women undergoing multimodality treatment for advanced stage endometrial carcinoma. Eligible participants must have FIGO stage III uterine carcinoma and be candidates for combined modality treatment, which includes surgery, chemotherapy with carbo/Taxol, and radiation therapy. Patients with carcinosarcoma histology are excluded." |
| NCT05557838,"For Chinese patients with unresectable hepatocellular carcinoma (uHCC), what are the key eligibility criteria for a first-line treatment study combining Durvalumab and Tremelimumab, particularly regarding prior therapies, BCLC stage, and Child-Pugh score?","This study evaluates Durvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma (uHCC). Eligible patients must have confirmed HCC, no prior systemic therapy, at least one measurable lesion, and BCLC stage B (not eligible for locoregional therapy) or C. Child-Pugh score and ECOG performance status determine cohort assignment." |
| NCT04852926,"What are the specific demographic and treatment criteria for female patients with invasive breast carcinoma to be included in a study on sexual health, particularly those undergoing chemotherapy and followed in a fertility observatory?","This study investigates the sexual health of female patients treated for breast cancer and followed up in the Observatory of Fertility at Jeanne de Flandre Hospital. Eligible participants are females aged 18 or older, in a relationship, with invasive breast carcinoma, and a planned medical therapy project by chemotherapy. Patients must provide written consent and be willing to follow all study procedures." |
| NCT04851834,"What are the general and disease-specific eligibility criteria for patients with advanced solid tumors, platinum-resistant ovarian/bladder cancer, or high-grade glioma to participate in a Phase 1 study of NTX-301 monotherapy or combination therapy?","This Phase 1 study evaluates NTX-301 monotherapy in advanced solid tumors and in combination with platinum-based chemotherapy for advanced ovarian/bladder cancer, or temozolomide for high-grade glioma. Eligible patients must have histologically confirmed advanced/metastatic cancer, be refractory or intolerant to standard therapies, and have an ECOG performance status of 0-1. Specific prior treatment and cardiac function criteria apply." |
| NCT05111314,"For patients with hepatocellular carcinoma (HCC) undergoing planned hepatic artery embolization (HAE), what are the specific diagnostic and imaging criteria for inclusion in a study comparing hepatic intraarterial versus systemic intravenous 68Ga-PSMA PET/CT for HCC detection?","This diagnostic study compares hepatic intraarterial versus systemic intravenous 68Ga-PSMA PET/CT for detecting hepatocellular carcinoma (HCC). Eligible patients must have an imaging diagnosis of HCC (LI-RADS 5) or biopsy-proven HCC, show PSMA avid HCC by IV 68Ga-PSMA PET/CT, and be undergoing planned hepatic artery embolization. Pregnant/breastfeeding subjects are excluded." |
| NCT06105021,"What are the specific genetic and disease progression criteria for patients with advanced or metastatic solid tumors, including NSCLC, colorectal cancer, or pancreatic ductal adenocarcinoma, to be eligible for a Phase I study of autologous CD8+ and CD4+ engineered T cell receptor T cells targeting KRAS G12V?","This Phase I study evaluates autologous CD8+ and CD4+ engineered T cell receptor T cells in subjects with advanced or metastatic solid tumors, including pancreatic ductal adenocarcinoma, NSCLC, and colorectal cancer. Eligible patients must have confirmed KRAS G12V mutational status and the HLA-A*11:01 allele. They must have progressed on or be intolerant of at least one prior line of standard systemic therapy." |
| NCT06880198,"For patients with unresectable locally advanced or metastatic cutaneous melanoma, what are the key eligibility criteria for a study evaluating Impact® as support to anti-PD1 or anti-PD1 based regimen treatment, considering PD-L1 status and prior therapies?","This study evaluates Impact® as support to anti-PD1 or anti-PD1 based regimen treatment in patients with inoperable locally advanced or metastatic cutaneous melanoma. Eligible participants must be aged 18 or older, have histologically confirmed stage III (unresectable) or stage IV cutaneous melanoma, and have a planned anti-PD1 or anti-PD1 based regimen. Patients with active brain metastases are excluded." |
| NCT04293289,What are the specific tumor characteristics and prior treatment status requirements for patients with malignant melanoma or angiosarcoma to be eligible for Boron Neutron Capture Therapy using CICS-1 and SPM-011?,"This study investigates Boron Neutron Capture Therapy using CICS-1 and SPM-011 for malignant melanoma and angiosarcoma. Eligible patients must have primary malignant melanoma or angiosarcoma with superficial skin lesions, a maximum diameter of 15 cm or less, and a depth of 6 cm or less from the skin surface. Patients must have failed first-line treatment, be medically unfit for standard of care, or refuse it." |
| NCT03780608,What are the specific disease progression and prior treatment criteria for patients with advanced gastric adenocarcinoma or metastatic melanoma to be eligible for a Phase II study of AZD6738 in combination with Durvalumab?,"This Phase II study evaluates AZD6738 in combination with Durvalumab in patients with solid tumors, specifically gastric adenocarcinoma and malignant melanoma. Cohort A includes patients with advanced gastric adenocarcinoma who have failed secondary chemotherapy. Cohort B includes metastatic melanoma patients who have progressed on prior anti-PD(L)1 therapy. ATM expression status is assessed prospectively." |
| NCT02054104,What are the specific disease types and residual disease status requirements for patients with thoracic malignancies or metastases to the lungs/pleura to be eligible for an adjuvant tumor lysate vaccine study?,"This study investigates an adjuvant tumor lysate vaccine and Iscomatrix with or without metronomic oral cyclophosphamide and celecoxib in patients with malignancies involving the lungs, esophagus, pleura, or mediastinum. Eligible patients must have histologically or cytologically proven thoracic cancers or metastases, with no clinical evidence of active disease (NED) or minimal residual disease (MRD) following standard therapy. Patients requiring chronic systemic steroid treatment are excluded." |
| NCT01222728,"For patients with Neurofibromatosis Type II (NF2), what are the specific tumor burden and type requirements to be eligible for a study using Positron Emission Tomography (PET) to predict intracranial tumor growth?","This diagnostic/observational study uses Positron Emission Tomography (PET) to predict intracranial tumor growth in Neurofibromatosis Type II (NF2) patients. Eligible participants must have a clinical diagnosis of NF2, be aged 18-50, and have a minimum of three intracranial tumors (meningiomas and/or vestibular schwannomas) measuring ≥ 1cm, including at least one unoperated VS and one unoperated meningioma." |
| NCT04755465,What are the hematological and performance status criteria for patients with hematological cancer to participate in a study evaluating the effects of NMES and exercise on muscle weakness?,"This therapeutic study investigates the effects of NMES and exercise in patients with hematological cancer experiencing muscle weakness. Eligible participants must be diagnosed with hematological cancer, be ≥ 18 years old, and have an ECOG Performance Status between 1-3. Specific laboratory values for hemoglobin, platelets, and leukocytes are also required." |
| NCT02825836,"What are the disease status and prior treatment requirements for patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) to be eligible for a Phase I/II first-in-human dose escalation trial of TL-895, either as monotherapy or in combination with Navtemadlin?","This Phase I/II first-in-human dose escalation trial evaluates TL-895 as monotherapy and in combination with Navtemadlin for B-cell malignancies. Eligible patients include those with relapsed/refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), as well as treatment-naïve CLL or SLL, depending on the study arm. Patients must have an ECOG performance status ≤ 2 and adequate organ functions." |
| NCT05397171,"What are the general and substudy-specific eligibility criteria for patients with selected advanced/metastatic solid tumors, such as NSCLC, MSS-CRC, or UC, to participate in a first-in-human study of AZD8853?","This first-in-human study evaluates the safety and tolerability of AZD8853 in participants with selected advanced/metastatic solid tumors. General inclusion criteria include at least one measurable target lesion, ECOG 0-1, and a life expectancy of ≥ 12 weeks. For Substudy 1, patients must have histologically confirmed locally advanced, unresectable or metastatic NSCLC, MSS-CRC, or UC with documented progression from previous therapy." |
| NCT05457309,What are the specific wound characteristics and cancer diagnosis requirements for breast cancer patients to be included in a study evaluating a malignant fungating wounds care regimen?,This study focuses on the construction and effect evaluation of a malignant fungating wounds care regimen for breast cancer patients. Eligible participants must be aged 18 or older with a pathologically confirmed diagnosis of breast cancer. They must have tumor metastasis in the chest wall or other sites that has ruptured to form a malignant fungating wound with a wound area of at least 10cm2. |
| NCT02482532,"What are the disease stage and treatment status requirements for patients with melanoma to be eligible for a study involving vaccine-enriched, autologous, activated T-cells directed to the tumor?","This therapeutic study evaluates vaccine enriched, autologous, activated T-cells directed to tumor in patients with relapsed/refractory melanoma. Eligible participants must have metastatic, surgically unresectable melanoma or newly diagnosed melanoma of any stage where standard therapy is not feasible. Patients must have a life expectancy of at least 12 weeks and an ECOG performance score of ≤ 2." |
| NCT03420963,"What are the age, performance status, and disease characteristics for children and young adults with relapsed or refractory solid tumors to be eligible for a study involving donor natural killer cells, cyclophosphamide, and etoposide?","This therapeutic study investigates donor natural killer cells, cyclophosphamide, and etoposide in treating children and young adults with relapsed or refractory solid tumors. Eligible participants must have relapsed or refractory solid tumors without known curative therapy, a Karnofsky performance status ≥ 60% (or Lansky for younger patients), and measurable or evaluable disease. Patients over 21 must have a solid tumor considered of the childhood cancer type." |
| NCT06414421,What are the general health and neurological exclusion criteria for patients undergoing prostate biopsy to participate in a study evaluating the effect of Transcutaneous Electrical Nerve Stimulation (TENS) on pain and comfort?,"This therapeutic study evaluates the effect of Transcutaneous Electrical Nerve Stimulation (TENS) on pain, complications, and comfort in patients undergoing prostate biopsy with transrectal ultrasound. Eligible participants must be over 40 years old, able to communicate, and have no previous history of chronic pain or bleeding diathesis. Key exclusion criteria include cognitive impairment, neurological or psychiatric disease, and contraindications for electrotherapy like pacemakers." |
| NCT07377006,What are the specific patient population and communication requirements for prostate cancer patients to be included in a study evaluating a decision support tool for germline genetic testing?,This diagnostic/observational study evaluates a decision support tool to enhance germline genetic testing for patients with prostate cancer. Eligible participants are diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital who were recommended for germline genetic testing by their oncology provider. Patients must be able to provide informed consent and communicate in English or Spanish. |
| NCT05568433,What are the specific imaging and diagnostic criteria for patients with pancreatic cysts to be included in a study investigating new biomarkers in intracystic liquid?,"This diagnostic/observational study investigates new biomarkers in the intracystic liquid of inflammatory and non-inflammatory pancreatic cysts. Eligible participants are patients aged 18-90 years with an unclear specific diagnosis of pancreatic cysts, or pancreatic cysts >15mm on CT or MRI. Patients with pseudocysts with an indication for drainage are also included." |
| NCT02930252,"For patients with malignant obstructive biliary disease, what are the key clinical and disease characteristics required for eligibility in a study comparing covered versus uncovered self-expandable metallic stents (SEMS)?","This comparative/therapeutic study compares covered versus uncovered Self-Expandable Metallic Stents (SEMS) for palliation of malignant biliary strictures. Eligible patients must have malignant obstructive disease at the extrahepatic bile duct, a serum bilirubin >50 micromol/L, and be inoperable due to poor medical condition or unresectable disease. Patients with a WHO performance score of 4 or life expectancy < 90 days are excluded." |
| NCT01815749,"What are the specific disease subtypes, remission status, and prior treatment requirements for patients with Non-Hodgkin Lymphoma (NHL) to be eligible for a Phase I/II study of genetically modified T-cell infusion following peripheral blood stem cell transplant?","This Phase I/II study investigates genetically modified T-cell infusion following peripheral blood stem cell transplant in patients with recurrent or high-risk Non-Hodgkin Lymphoma (NHL). Eligible participants must have an indication for HSCT, be diagnosed with intermediate grade B-cell NHL (e.g., DLBCL, MCL), and have recurrence/progression or high-risk disease in first remission. Patients must have a Karnofsky performance status ≥ 70%." |
| NCT04257058,What are the age and prior treatment history requirements for young adult survivors of pediatric cancer to participate in a study evaluating education tools to support survivor care?,"This supportive care/observational study evaluates education tools to support pediatric survivor care. Eligible participants must be 18-25 years of age, diagnosed with cancer at ≤ 18 years of age, and be at least 2 years since their last cancer treatment. They must also have been seen at least once in the Aflac Cancer Survivor Program (CSP) or transitioned out to adult survivor care since 2013." |
| NCT03642626,"What are the specific age, disease status, and prior treatment requirements for pediatric and adult patients with various hematologic malignancies (e.g., B-cell ALL, large B-cell lymphoma, mantle cell lymphoma, multiple myeloma) to be eligible for different arms of a CAR-T cell therapy study?","This therapeutic study investigates CAR-T cell therapy (Kymriah, Tecartus, Yescarta, Breyanzi, Abecma) for various hematologic malignancies. Eligibility is arm-specific: for B-cell ALL, patients must be relapsed/refractory with specific disease statuses and age ranges (0-25 or >18). For large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma, adult patients must have relapsed/refractory disease after specific prior therapies." |
| NCT04703985,"For patients with lymphoma or myeloma undergoing therapeutic intensification with autologous hematopoietic cells, what are the key inclusion criteria for a study evaluating prophylactic enteral nutrition?","This supportive care/therapeutic study evaluates the success of prophylactic enteral nutrition in therapeutic intensification with autograft of autologous hematopoietic cells in hematology patients. Eligible participants must have lymphoma or myeloma, be admitted for therapeutic intensification with autologous hematopoietic cells, and be eligible for nutritional support by enteral nutrition. Patients refusing enteral nutrition or with contraindications like intestinal obstruction are excluded." |
| NCT00720785,What are the specific disease types and prior treatment resistance criteria for patients with metastatic solid tumors or hematological malignancies to be eligible for a study combining Natural Killer Cells and Bortezomib?,"This therapeutic study investigates Natural Killer Cells and Bortezomib to treat cancer. Eligible participants include those with histologically confirmed metastatic solid tumors (e.g., lung, pancreatic, colorectal cancer) resistant or refractory to standard treatments, or hematological malignancies (e.g., multiple myeloma, CML, CLL/SLL) resistant or refractory to standard therapy. Patients with brain metastases (unless treated and small) or peripheral neuropathy > grade 1 are excluded." |
| NCT00072215,"For men with progressive or recurrent metastatic germ cell tumors (GCTs), what are the specific prior treatment and resistance criteria to be eligible for a study comparing cisplatin and ifosfamide combined with either paclitaxel or vinblastine?","This therapeutic study compares Cisplatin and Ifosfamide combined with either Paclitaxel or Vinblastine in treating men with progressive or recurrent metastatic germ cell tumors (GCTs). Eligible patients must have histologically confirmed GCT with metastatic disease, and have previously been treated with one regimen of etoposide and cisplatin +/- bleomycin, exhibiting clinical resistance. Patients must have adequate organ function." |
| NCT02404363,"What are the specific disease stage, prior treatment, and performance status requirements for patients with locally advanced or metastatic pancreatic adenocarcinoma to be eligible for a study evaluating Clopidogrel in combination with chemotherapy?","This therapeutic study evaluates the safety and efficacy of Clopidogrel in locally advanced and metastatic pancreatic adenocarcinoma treated with chemotherapy. Eligible participants must be 18 years or older with histologically confirmed adenocarcinoma of the pancreas, locally advanced or metastatic disease, and measurable lesions. Patients must not have received previous chemotherapy in either an adjuvant or metastatic setting and have an ECOG performance status of 0 or 1." |
| NCT01727921,What are the basic demographic and imaging requirements for patients with pancreatic or peripancreatic masses to be eligible for a comparative study of 22 and 25 gauge ProCore EUS-guided biopsy?,This comparative study evaluates 22 and 25 Gauge ProCore EUS-guided biopsy in pancreatic mass. Eligible participants must be 18 years of age or older and have a pancreatic or peripancreatic mass identified in imaging studies. Patients with contraindications to endoscopy or cardiopulmonary dysfunction are excluded. |
| NCT04996316,What are the age and technological access requirements for women to be included in a study evaluating the MammoScreen Breast Cancer Risk Assessment and Decision Aid for screening and referrals?,This diagnostic/observational study evaluates the MammoScreen Breast Cancer Risk Assessment and Decision Aid for breast cancer screening and referrals. Eligible participants are women between the ages of 40 and 74 who are enrolled in MyChart and able to read English. Patients with a personal history of breast or ovarian cancer or who are currently pregnant are excluded. |
| NCT02685306,"For patients with early-stage triple-negative breast cancer (TNBC), what are the specific pathological confirmation, staging, and hormone receptor/HER2 status requirements for eligibility in a study of neoadjuvant Paclitaxel in combination with Bavituximab?","This therapeutic study investigates neoadjuvant Paclitaxel in combination with Bavituximab in early-stage triple-negative breast cancer (TNBC). Eligible participants are females or males aged at least 18 with invasive breast cancer confirmed by pathology. Tumors must be early-stage TNBC (AJCC Clinical Stage I, II, or III), defined as ER/PgR negative (<1%) and HER2 non-overexpressed or amplified." |
| NCT06280040,"For a newly diagnosed uveal melanoma patient, what are the key eligibility criteria for the longitudinal follow-up study involving hypofractionated stereotactic photon radiotherapy?","This study, NCT06280040, is a longitudinal follow-up for patients with newly diagnosed uveal melanoma treated with hypofractionated stereotactic photon radiotherapy as part of clinical routine. Key inclusion criteria require patients to have newly diagnosed uveal melanoma and be treated with this specific radiotherapy. Patients unwilling to participate or with severe media opacity are excluded. The primary objective is to longitudinally follow these patients." |
| NCT00757614,"What are the geographic and disease-specific eligibility requirements for patients to participate in the ""Study of Genes and Environment in Patients With Cancer"" in the United Kingdom?","This study (NCT00757614) investigates genes and environment in patients with various cancers, including bladder, kidney, esophageal, pancreatic, brain, malignant melanoma, or lymphoma. Patients must have been diagnosed within the past 5 years and identified through the Cancer Research Network or registries in East Anglia, West Midlands, or Trent regions of the UK. Participants must be deemed fit to contact by their general practitioner and have no serious mental illness." |
| NCT00767533,"What are the broad inclusion and exclusion criteria for adults participating in the ""Immunobiology of Cancer"" study, particularly regarding cancer status and autoimmune disorders?","The ""Immunobiology of Cancer"" study (NCT00767533) includes participants aged 18 or over who either have cancer or do not have cancer and/or an autoimmune disorder. The primary objective is to study the immunobiology of cancer. Participants with an autoimmune disorder and/or those under 18 years of age are excluded." |
| NCT00003308,"For a patient with metastatic melanoma and newly diagnosed brain metastases, what are the specific size, location, and prior treatment criteria for eligibility in the radiation therapy study NCT00003308?","This study (NCT00003308) investigates radiation therapy for patients with newly diagnosed brain metastases from kidney cancer, melanoma, or sarcoma. Patients must have 1-3 intraparenchymal brain metastases, with no single lesion exceeding 4.0 cm and no more than one exceeding 3.0 cm if multiple. Exclusions include metastases in critical brain regions (brain stem, optic nerve) or prior cranial radiotherapy. Patients must have an ECOG 0-2 and a life expectancy of at least 3 months." |
| NCT02571036,"What are the specific molecular and disease progression criteria for GIST patients to be eligible for the Phase 1 safety, tolerability, and PK study of DCC-2618?","This Phase 1 study (NCT02571036) evaluates the safety, tolerability, and pharmacokinetics of DCC-2618 in patients with advanced malignancies. For GIST patients, inclusion requires histologically confirmed KIT and PDGFRA mutations and progression or intolerability to at least one prior line of systemic anticancer therapy. Patients must have an ECOG performance status of ""≤2"" and adequate organ function." |
| NCT02459067,What are the primary disease and performance status requirements for patients with advanced malignant melanoma to be considered for the ImmuniCell® study?,"The ImmuniCell® study (NCT02459067) is for patients with advanced malignant melanoma, renal cell carcinoma, or NSCLC who are refractory to standard treatments or have indolent disease potentially benefiting from immunotherapy. Patients must have an ECOG performance status of 0 or 1, measurable disease per irRC criteria, and adequate bone marrow, liver, and renal function. A life expectancy of at least 3 months is also required." |
| NCT01425749,"What are the specific disease stage and molecular marker requirements for melanoma patients to be eligible for the MAGE-A3 ASCI safety and immune response study, especially concerning prior treatment and brain metastases?","This study (NCT01425749) assesses the safety and immune response of MAGE-A3 ASCI in resected melanoma. Patients must have histologically confirmed Stage IIB-IV melanoma, rendered clinically disease-free or with non-measurable disease, and their tumor must express MAGE-A3. Patients with treated brain metastases are eligible under strict conditions, including complete removal or stereotactic radiotherapy, no growth, and lesions no larger than 2 cm. An ECOG performance status of 0-1 is required." |
| NCT03302637,"What are the specific sample requirements for inclusion in the ""Oral Microbiome and Pancreatic Cancer"" study?","The ""Oral Microbiome and Pancreatic Cancer"" study (NCT03302637) focuses on analyzing DNA from oral wash samples. The primary inclusion criterion is the availability of DNA extracted from oral wash samples from the NIH-PLCO and ACS-CPS cohorts. There are no specific exclusion criteria listed for this study." |
| NCT01471054,What are the specific ocular and treatment history criteria for patients with uveal melanoma and macular edema to be eligible for the Dexamethasone Intravitreal Implant study?,"This study (NCT01471054) evaluates a dexamethasone intravitreal implant for macular edema after plaque radiotherapy of uveal melanoma. Eligible patients must have uveal melanoma treated with I-125 plaque radiotherapy, visual acuity between 20/40 and 20/400 due to post-radiation macular edema, and a central subfield retinal thickness >300 microns. The macular edema duration must be less than 12 months, and patients must not have received periocular, intravitreal, or systemic steroids within 6 months." |
| NCT06608420,"What are the fundamental inclusion and exclusion criteria for patients participating in the ""Precision Medicine for L/GCMN and Melanoma 1"" study?","The ""Precision Medicine for L/GCMN and Melanoma 1"" study (NCT06608420) includes melanoma patients of any age with histopathologically confirmed melanoma. Patients without a melanoma diagnosis, those who have not signed informed consent, or those with records prior to the year 2012 are excluded. The study aims to advance precision medicine for melanoma." |
| NCT04164082,What are the specific disease characteristics and prior treatment requirements for patients with BCG-unresponsive non-muscle invasive bladder cancer to be eligible for the study combining Pembrolizumab with Gemcitabine?,"This study (NCT04164082) investigates Pembrolizumab with Gemcitabine for BCG-unresponsive non-muscle invasive bladder cancer. Eligible patients must have high-grade Ta, T1, or CIS urothelial carcinoma with persistent disease after adequate BCG therapy, and be unfit for or refuse radical cystectomy. Key exclusion criteria include prior anti-PD-1/PD-L1/CTLA-4 therapy and active autoimmune disease requiring systemic treatment within 24 months." |
| NCT04557956,"For patients with BRAF-mutated metastatic melanoma who have progressed on BRAF/MEK inhibitor therapy, what are the eligibility criteria for the study testing Tazemetostat in combination with Dabrafenib and Trametinib?","This study (NCT04557956) evaluates Tazemetostat with Dabrafenib and Trametinib for BRAF V600E/K-mutated metastatic melanoma that has progressed on prior BRAF/MEK inhibitor therapy. Patients must have an ECOG performance status "">2"" is an exclusion, so ""≤2"" is required. Those with symptomatic CNS metastases are eligible if previously treated and stable for 4 weeks on stable/tapering steroids. Prior EZH2 inhibitor therapy is an exclusion." |
| NCT03025256,What are the specific diagnostic and prior treatment requirements for patients with leptomeningeal disease from metastatic melanoma or lung cancer to be eligible for the Intravenous and Intrathecal Nivolumab study?,"This study (NCT03025256) investigates intravenous and intrathecal Nivolumab for leptomeningeal disease (LMD) in patients with metastatic melanoma or lung cancer. Patients must have radiographic and/or CSF cytological evidence of LMD and an ECOG performance status "">2"" is an exclusion, so ""≤2"" is required. Prior radiation to the brain/spine is allowed if completed "">=7"" days prior, and approved targeted therapies (e.g., BRAF/MEK inhibitors) can be continued concurrently." |
| NCT01274533,What are the key eligibility criteria for patients with relapsed or refractory HTLV-1 associated Adult T-cell Leukemia/Lymphoma to participate in a Lenalidomide study?,"This study (NCT01274533) investigates Lenalidomide in patients with relapsed or refractory HTLV-1 associated Adult T-cell Leukemia/Lymphoma. Patients must have an ECOG performance status of "">2"" is an exclusion, so ""≤2"" is required and adequate bone marrow, renal, and hepatic function. All previous cancer therapy must have been discontinued at least 4 weeks prior to treatment. Patients at high risk for DVT/PE must be able to take aspirin or other prophylactic anticoagulation." |
| NCT06287944,"What are the specific age, disease risk, and donor matching criteria for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome to be eligible for the 225Ac-DOTA-Anti-CD38 Daratumumab conditioning regimen prior to donor stem cell transplant?","This study (NCT06287944) uses 225Ac-DOTA-Anti-CD38 Daratumumab with Fludarabine, Melphalan, and TMLI as conditioning for donor stem cell transplant in high-risk AML, ALL, and MDS. Eligible patients are "">=60"" years (or "">=18"" with HCT-CI "">=2"") with high-risk disease or MRD-positive CR. A key criterion is the availability of an HLA-identical sibling or 10/10 matched unrelated donor. Patients with prior radiotherapy or radiopharmaceutical therapy are generally excluded." |
| NCT01366898,What are the primary age and disease characteristics for elderly patients with Acute Lymphoblastic Leukemia to be included in this treatment protocol?,"This protocol (NCT01366898) is for the treatment of Acute Lymphoblastic Leukemia (ALL) in elderly patients. Inclusion criteria specify adults over 55 years diagnosed with Ph-negative ALL who are treatment-naïve. Patients with L3 ALL with mature B phenotype, biphenotypic/bilinear leukemias, or acute undifferentiated leukemia are excluded from treatment." |
| NCT06564493,"What are the critical age, disease status, and donor requirements for pediatric ALL patients to be eligible for the randomized controlled study of MSD-HSCT using TBI or TMLI conditioning?","This randomized controlled study (NCT06564493) investigates MSD-HSCT using TBI or TMLI conditioning for pediatric ALL. Eligible participants are male or female, aged 1-17 years, diagnosed with ALL, and must be in hematologic remission (complete remission, CR) prior to transplantation. A suitable matched sibling donor is required, and patients must have a Karnofsky score of 70 or higher with no significant organ dysfunction." |
| NCT01795716,What are the key demographic and health status criteria for Chronic Myeloid Leukemia patients to be eligible for the bioequivalence study of Mesylate Imatinib Capsule?,"This study (NCT01795716) is a bioequivalence study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia patients. Eligible participants are aged 18-65 years, with a confirmed CML diagnosis, ECOG performance status 0-3, and a life expectancy greater than 3 months. Patients must have adequate hepatic, renal, and bone marrow function, and no prior radiation, chemotherapy, or surgery within one week of treatment." |
| NCT00697684,"What are the criteria for patients with hematologic malignancies to be considered ""appropriate for reduced intensity transplantation"" in the study using Clofarabine, ATG, and TLI followed by allogeneic stem cell transplant?","This study (NCT00697684) uses a reduced intensity conditioning regimen with Clofarabine, ATG, and TLI followed by allogeneic stem cell transplant for various hematologic cancers. Patients are considered appropriate for reduced intensity transplantation if they are over 50, have a history of prior HCT, compromised organ function, or have low-grade lymphoma/CLL. They must have a 5/6 or 6/6 HLA-matched related or unrelated donor and an ECOG performance status of 0-2." |
| NCT03132948,What are the age and health requirements for pediatric patients with Acute Lymphoblastic Leukemia to participate in a quality of life study during maintenance chemotherapy?,"This study (NCT03132948) assesses quality of life in pediatric ALL patients receiving maintenance chemotherapy. Eligible patients are aged 8-18, must be in the maintenance phase of chemotherapy, and be English-speaking. They should have no documented psychiatric or neurological disorders that would interfere with study participation and no contraindications to moderate physical exercise." |
| NCT00552825,"What are the specific age and disease type criteria for pediatric patients to be included in the ""Pulmonary Function at Presentation and Follow-up in Hemato-Oncology"" study?",This study (NCT00552825) focuses on pulmonary function in pediatric hemato-oncology patients. It includes all pediatric patients aged 3-7 years with hemato-oncologic diseases who were treated at the Hemato-Oncology Department and referred to the pediatric pulmonary unit. The study aims to follow up on their pulmonary function. |
| NCT02885038,What are the specific patient population and treatment history requirements for inclusion in the study on the effect of product-related factors on platelet concentrate transfusion response in hematologic malignancies?,"This study (NCT02885038) investigates the effect of product-related factors on platelet concentrate transfusion response in patients with hematologic malignancies. Eligible participants are inpatients aged 18 or over with a hematologic malignancy (lymphoma, multiple myeloma, lymphocytic leukemia, Hodgkin disease) who received at least one platelet transfusion with a platelet count "">=25"" G/L. Patients with more than one hematologic malignancy or non-malignant hematological disorders are excluded." |
| NCT00083213,"For patients with relapsed or refractory advanced solid tumors, what are the specific disease location and prior treatment requirements for eligibility in the Intravenous VEGF Trap study?","This study (NCT00083213) investigates Intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors or Non-Hodgkin's Lymphoma. Patients must have histologically confirmed disease refractory to standard therapies, with measurable lesions in specific sites like liver or soft tissue. Key exclusions include prior or concurrent CNS metastases and histologically confirmed squamous cell carcinoma of the lung. Patients must have an ECOG 0-2 and adequate organ function. |
| This study (NCT00520208) evaluates the safety and efficacy of Tamibarotene in patients with relapsed or refractory Acute Promyelocytic Leukemia (APL). Eligibility requires confirmed APL diagnosis (t(15;17), PML/RAR-α RT-PCR, or FISH) and documented failure of ATRA and ATO-based therapy. Patients must have an ECOG performance status >2 is an exclusion, so ≤2 is required and an estimated life expectancy of >=12 weeks. |
| This study (NCT04002115) uses Clofarabine pre-conditioning followed by stem cell transplant for non-remission AML. Eligible patients have AML with induction failure (after >=2 attempts) or relapsed after complete remission, are aged 18-75, and are planned for allogeneic HSCT from haploidentical, matched, or mismatched unrelated donors. Patients must have a Karnofsky performance status >=70% and adequate organ function. |
| For patients with Chronic Myelogenous Leukemia in chronic phase on first-line imatinib, what are the specific molecular response and treatment duration criteria for eligibility in the study combining Imatinib and Valproic Acid?This study (NCT01011998) investigates Imatinib and Valproic Acid in Chronic Myelogenous Leukemia (CML) patients. Eligible patients must be in chronic phase CML, on imatinib as first-line therapy for at least 9 months, and show a relative plateau in bcr-abl RT-PCR levels over the last two tests (at least 3 months apart). Patients must be >=18 years old, have an ECOG performance status of 0-2, and adequate hepatic and renal function. |
| |
| This study (NCT06830733) evaluates the safety and efficacy of ARI0002h for the initial treatment of primary plasma cell leukemia. Eligible patients are between 18 and 75 years old with newly diagnosed primary plasma cell leukemia, measurable disease, and an ECOG performance status of 0-2. Up to two cycles of previous treatment for symptomatic control are allowed, but prior anti-BCMA therapy is an exclusion. |
| For patients with relapsed or refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, what are the specific prior treatment and cardiac function criteria for eligibility in the AVENUE-2 trial combining Acalabrutinib with Venetoclax?The AVENUE-2 trial (NCT04941716) investigates Acalabrutinib with Venetoclax for relapsed/refractory CLL or SLL. Patients must have active disease requiring treatment and have failed at least one prior systemic therapy. Key exclusions include prior disease progression on a BTK inhibitor or venetoclax, and clinically significant cardiovascular disease (NYHA Class III/IV, MI within 6 months, QTc >480 ms). |
| What are the specific age, pulmonary function, and medication restrictions for women with Lymphangioleiomyomatosis (LAM) to be eligible for the long-term safety and tolerability study of Imatinib?This study (NCT06889168) evaluates the long-term safety and tolerability of Imatinib in women with Lymphangioleiomyomatosis (LAM). Eligible participants are women aged 18-64 years with confirmed or possible LAM, and specific pulmonary function criteria (DLCO >20% predicted and FVC <90% OR FEV1 30-90% predicted). Exclusion criteria include pregnancy, planned surgery/transplant, and current use of certain antifungal, antibiotic, analgesic, antiretroviral, anti-epileptic, or antidepressant medications. |
| This study (NCT01634217) investigates inducible Regulatory T Cells (iTregs) in non-myeloablative sibling donor peripheral blood stem cell transplantation for various hematologic malignancies. Eligible patients are 18-75 years old with an HLA-identical sibling donor and specific disease statuses, such as high-risk CR1/CR2+ AML/ALL, CML (except blast crisis), chemosensitive NHL/HL, MDS with severe pancytopenia, or MM. Patients must have a Karnofsky performance status >=60% and adequate organ function. |
| For patients with relapsed or refractory Peripheral T-cell Lymphoma, what are the specific prior treatment and molecular inhibitor exposure criteria for eligibility in the randomized, double-blind, multicenter Phase III study of XNW5004 Tablets?This Phase III study (NCT06776952) evaluates XNW5004 Tablets in patients with relapsed or refractory Peripheral T-cell Lymphoma. Eligible patients must have pathologically diagnosed PTCL after at least one prior systemic treatment line, and must not have received prior HDAC inhibitors. Patients with NK/T-cell lymphoma require prior asparaginase/protease regimens, and CD30+ ALCL requires prior Brentuximab vedotin. An ECOG performance status of 0 or 1 and measurable lesions are required. |
| This study (NCT01761500) aims to improve the survival rate of Chinese children and adolescents with Non-Hodgkin's Lymphoma. Eligible participants are untreated children and adolescents aged "">=20"" years. Recurrent Non-Hodgkin's lymphoma and age >20 years are exclusion criteria. Informed consent from guardians is mandatory. |
| What are the specific disease refractory criteria and prior transplant history for patients with non-Hodgkin's lymphoma, Hodgkin's lymphoma, or multiple myeloma to be eligible for the study involving intentional rejection of the donor graft following nonmyeloablative allogeneic stem cell transplant?This study (NCT00909948) investigates intentional rejection of donor graft following nonmyeloablative allogeneic stem cell transplant for chemorefractory NHL, HL, or MM. Eligible patients have primary refractory or refractory relapsed disease, or relapse after autologous HCT, with an estimated disease-free survival of less than one year. Patients must be aged 18 to <75 years with an ECOG performance status of 0-2. |
| |
| This clinical trial (NCT06292208) evaluates IBD0333 in patients with advanced malignant tumors or non-Hodgkin lymphoma. Eligible patients must have histologically or cytologically confirmed locally advanced/metastatic solid tumor or non-Hodgkin lymphoma who have failed, have no standard therapy, or are intolerant to standard therapy. Patients must have at least one assessable/measurable lesion, an ECOG performance status of 0 or 1, and a life expectancy of at least 3 months. |
| This study (NCT05038150) investigates SGN1 in patients with advanced solid tumors. Eligible patients have advanced stage cancer (e.g., SCLC, NSCLC, sarcoma, melanoma) who have failed standard treatment, are intolerant to it, or have no standard options. Patients must have an ECOG performance status of 0-1, a life expectancy of at least 3 months, and adequate organ function. Prior anti-tumor therapy must have ended >=4 weeks before the first dose. |
| This study (NCT00901615) combines Lenalidomide and R-CHOP for patients with CD20 positive B-cell Lymphoma. Eligible histological subtypes include Mantle cell, Marginal zone, follicular, Diffuse large B cell, or histological transformation from low grade to high grade. Patients must be aged 18-70 years, have a WHO performance status of 0-2, and a life expectancy of at least 90 days. Prior immunotherapy or chemotherapy (with specific exceptions) is an exclusion. |
| For patients with relapsed and refractory Diffuse Large B-cell Lymphoma, what are the specific disease characteristics and prior treatment criteria for eligibility in the study combining novel targeted drugs with R-ICE regimen?This study (NCT05348213) investigates novel targeted drugs combined with the R-ICE regimen in relapsed and refractory Diffuse Large B-cell Lymphoma (DLBCL). Eligible patients must have histologically confirmed DLBCL (excluding primary CNS/HIV-associated), evaluable lesions by PET/CT, and a life expectancy >3 months. They must have failed sufficient first-line anti-lymphoma therapy or experienced early relapse, and be aged 18-75 with an ECOG performance status of 0-2. |
| What are the specific histological grade, stage, and prior treatment status requirements for patients with Follicular Lymphoma to be eligible for the fixed-duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) study?This study (NCT07126678) evaluates fixed-duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in treatment-naïve advanced stage Follicular Lymphoma. Eligible patients must have histologically confirmed grade I, II, or IIIa FL, be treatment-naïve, have stage III-IV disease, and meet GELF criteria. Patients must be aged 18-75 years with an ECOG performance status of 0-2 (or 3 if disease-related). Grade IIIb FL or transformed FL are exclusion criteria. |
| What are the eligibility criteria for patients with advanced melanoma to participate in a Phase 1b study of Durvalumab and Trametinib, specifically regarding prior treatments and molecular status?This Phase 1b study (NCT02010040) investigates Durvalumab and Trametinib in MSS metastatic colorectal cancer. Patients must have histologically confirmed metastatic colorectal cancer with measurable disease and have received at least prior treatment with a fluoropyrimidine and either oxaliplatin or irinotecan. Key eligibility includes known MSS status, known or evaluable BRAF and KRAS status, and an ECOG performance status of 0-1. Patients with known brain metastases or prior T-cell checkpoint inhibitor therapies are excluded. |
| This study (NCT00091689) evaluates the safety and efficacy of an immune response modifier to treat inoperable advanced melanoma skin lesions. Eligible patients must have unresectable melanoma cutaneous metastasis or lentigo maligna melanoma for which standard curative or palliative measures are ineffective. Patients need an ECOG performance status >=2 is an exclusion, so ≤2 is required, a life expectancy of at least 4 months, and normal organ and bone marrow function. Exclusion criteria include a BMI >30 kg/m2, history of myocardial ischemia, congestive heart failure, or myocardial arrhythmias within 6 months. |
| What are the specific melanoma stages and treatment history requirements for patients to be included in the focus group and survey recruitment for the study on health behaviors, psychosocial factors, and family concerns?This study (NCT00518050) investigates health behaviors, psychosocial factors, and family concerns in melanoma survivors. For focus group recruitment, patients with invasive primary cutaneous melanoma (stages I-III) treated at MSKCC from 1996-2005 are eligible. For the survey group, patients with the same melanoma type treated from 2001-2011 are included. Patients with in situ or stage IV melanoma, or those still receiving treatment for melanoma one year post-diagnosis, are excluded. |
| What are the key eligibility criteria for patients with metastatic or unresectable malignant melanoma to participate in the IL-2 SELECT Tissue Collection Protocol?The IL-2 SELECT Tissue Collection Protocol (NCT01288963) is for patients with malignant melanoma that is metastatic or unresectable. Eligible patients must be candidates to receive high-dose IL-2 and have an available tissue block with adequate tumor for RNA extraction and DASL analysis. Patients with prior immunotherapy for unresectable or metastatic disease, or untreated brain metastases, leptomeningeal disease, or seizure disorder are excluded. |
| What are the specific molecular and disease stage requirements for melanoma patients to be eligible for the Nilotinib efficacy study, particularly regarding c-KIT mutations and prior therapies?This study (NCT01168050) evaluates the efficacy of Nilotinib in first or second-line treatment of primary or unresectable Stage III/IV melanomas. Eligible patients must have histologically proven melanoma with either a c-KIT mutation or c-KIT amplification (without BRAF or NRAS mutation) and measurable disease. Patients should have no more than one previous specific therapy (excluding tyrosine kinase inhibitors) and an ECOG performance status <2 is required. Active cerebral metastases are an exclusion. |
| This study (NCT04223648) investigates Programmed Cell Death 1 + Selected Cell Therapy with Durvalumab and Tremelimumab in untreated metastatic melanoma. Patients must have a metastatic lesion >=1.5 cm for surgical removal and at least one measurable RECIST 1.1 target lesion. Key exclusion criteria include prior treatment for metastatic melanoma, prior cell transfer therapy, or anti-PD-1 immune therapy within 6 months. Patients with active or prior documented autoimmune or inflammatory disorders are generally excluded, with specific exceptions like vitiligo. |
| This study (NCT01469455) investigates a DNA Repair Inhibitor & Irradiation on local metastatic melanoma. Eligible patients must have histologically confirmed metastatic melanoma with relapsed cutaneous tumors, not eligible for immediate surgery or refractory to conventional treatment. They need at least two measurable tumors ≤4 cm in diameter, not previously irradiated. Patients with known or suspected CNS metastases are excluded, unless previously treated, asymptomatic for >3 months, and off steroids/anticonvulsants for 14 days. |
| This study (NCT05361174) investigates the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or Stage III/IV NSCLC. For melanoma, participants must have progressed within 12 weeks of the last dose of anti-PD-1/PD-L1 blocking antibody, and if BRAF-mutated, also received a BRAF/MEK inhibitor. Patients with uveal/ocular melanoma are excluded. An ECOG performance status of 0 or 1 is required. |
| What are the specific transplant history and prior skin cancer history requirements for kidney, liver, heart, or lung transplant recipients to be eligible for the Skin Cancer Prevention with Nicotinamide pilot trial?This pilot trial (NCT03769285) investigates skin cancer prevention with Nicotinamide in transplant recipients. Eligible patients must be >=18 years old, have received a kidney, liver, heart, or lung transplant at least two years ago, and have a history of at least one prior histologically-confirmed keratinocyte carcinoma or squamous cell carcinoma in situ. Exclusion criteria include use of mTOR inhibitors within 12 weeks, biopsy-confirmed acute rejection within 12 weeks, or invasive Stage II melanoma/Merkel cell carcinoma/metastatic skin cancer within 5 years. |
| What are the specific cancer types, stage, and psychiatric symptom criteria for patients with advanced cancer to be eligible for the Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy study?This study (NCT06416085) evaluates Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for patients with advanced cancer. Eligible patients must have a confirmed diagnosis of stage IV solid tumor, sarcoma, endocrine, or melanoma cancers, or stage 4 lymphoma, with an expected survival of >6 months. Patients must also have at least mild depressive symptoms (PHQ-9 >8). Exclusion criteria include primary brain cancer or brain metastases with clinically significant symptoms, or a history of bipolar I disorder, psychotic disorders, or active substance use disorders. |
| What are the specific age, histological confirmation, and high-risk factors required for older patients with non-melanoma skin cancer to be eligible for the study on hypofractionated radiotherapy strategy after surgery?This study (NCT05794035) investigates the impact of hypofractionated radiotherapy strategy after surgery for non-melanoma skin carcinomas in older patients. Eligible patients must be aged >=70 years, have pathology-confirmed invasive SCC or BCC, and at least one high-risk factor for recurrence (e.g., close margins, location/size, perineural invasion, recurrent disease). Patients with macroscopic incomplete resection or severe dementia are excluded. Life expectancy of >=6 months is required. |
| This study (NCT02862743) focuses on molecular characterization of advanced stage melanoma by blood sampling. Eligible patients must have histologically confirmed metastatic melanoma (Stage III unresectable or Stage IV), be older than 18 years, and consent to participate. Patients with metastatic tumors of doubtful origin (uncertain melanoma) are excluded. The study aims to characterize the disease using blood samples. |
| This study (NCT04066725) investigates Aspirin as a UV protectant in human subjects at risk for melanoma. Eligible participants must have at least two nevi (each >5 mm diameter) not clinically suspicious for melanoma that can be biopsied, and be older than 18. Exclusion criteria include pregnancy, breastfeeding, history of allergic reaction to ASA, severe asthma, bleeding disorders, peptic ulcer disease, or recent intense UV exposure. |
| This study (NCT04526730) evaluates neoadjuvant immunotherapy with Tavo + Electroporation in combination with Nivolumab for melanoma patients. Eligible patients must have a histologic diagnosis of melanoma, be considered surgically operable, and present with regional lymph node metastases, recurrence, or distant metastases. Measurable disease (RECIST v1.1) accessible for electroporation is required. Previous treatment with anti-PD1 or anti-PDL1 immunotherapy is an exclusion criterion. |
| What are the specific cancer types, treatment history, and time from completion of active therapy requirements for young adult cancer survivors to be eligible for the survivorship care study aimed at reducing symptoms?This study (NCT02192333) focuses on survivorship care to reduce symptoms in young adult cancer survivors. Eligible patients must have been diagnosed with invasive malignancy (e.g., breast, GI, GU, sarcoma, leukemia, lymphoma) and received therapeutic intervention. They must be between 1.0 and 4.99 years from the completion of active cancer-directed therapy and be in active follow-up. Prior visits to a survivorship clinic or receipt of a treatment summary/care plan are exclusion criteria. |
| This study (NCT03287817) evaluates CD19/22 CAR T Cells (AUTO3) for relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL). Eligible patients must have histologically confirmed DLBCL or large B cell lymphoma subsets (e.g., transformed FL, high-grade B cell lymphoma) and chemotherapy-refractory disease or relapse after >=2 lines of therapy or ASCT. Patients must have received rituximab and an anthracycline-containing regimen. Prior allogeneic HSCT is an exclusion. |
| This study (NCT05797948) investigates GZL Sequential CD19/CD22 CAR-T in relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Eligible patients must have histologically confirmed CD22+ and/or CD19+ aggressive B-cell NHL, with disease refractory to first-line therapy or early relapse within 12 months. Patients must have relapsed or progressed >=3 months after targeted CD19 therapy. Appropriate organ function and bone marrow reserve are also required. |
| The Brazilian Prospective Hodgkin Lymphoma Registry (NCT02589548) aims to collect data on previously untreated HL patients. Inclusion criteria require a diagnosis of previously untreated HL, clinical data including baseline information on disease localization and laboratory parameters at staging, features of treatment adopted, and assurance of follow-up updating for at least 5 years. Written informed consent is mandatory. |
| What are the specific disease stage, histological subtypes, and imaging requirements for patients with previously untreated limited stage Diffuse Large B Cell Lymphoma to be eligible for the PET Adapted Therapy and Non-invasive Monitoring study?This study (NCT03758989) investigates PET Adapted Therapy and Non-invasive Monitoring for previously untreated limited stage non-bulky DLBCL. Eligible patients must have limited stage non-bulky DLBCL (Lugano criteria), including grade 3B follicular lymphoma and transformed indolent lymphoma. Measurable disease assessable by FDG-PET showing involvement is required. Patients with bulky disease >10 cm or who are pregnant/breastfeeding are excluded. |
| What are the specific histological and molecular characteristics of B-cell lymphoma, along with prior treatment history, required for patients to be eligible for the CAR-T Cell Therapy Efficacy Enhancement study via Chidamide and PD-1 Inhibitor combination?This study (NCT07489989) aims to enhance CAR-T cell therapy efficacy in B-cell lymphoma via Chidamide and PD-1 Inhibitor combination. Eligible patients must have histologically or cytologically confirmed CD19 and/or CD22-positive large B-cell lymphoma (WHO 2016) with specific high-risk features at initial diagnosis or relapsed/refractory disease after adequate prior therapy. Patients must be aged 18-85, have an ECOG performance status of 0-2, and adequate organ function. Prior CAR-T cell therapy is an exclusion. |
| This is a Phase 1 study (implied by healthy volunteers) investigating the interaction of TAK-279 with other drugs in healthy adults. Participants must be non-smokers for at least 3 months, have a Body Mass Index (BMI) between 18.0 and 32.0 kg/m^2, and be medically healthy with no clinically significant medical history or abnormal lab profiles. The primary objective is to assess drug-drug interactions. The study is currently recruiting healthy volunteers. |
| This study, likely Phase 1, aims to evaluate drug interactions of TAK-279 in healthy adults. Exclusion criteria include a history of cancer within the last 5 years (with exceptions for successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix), active infections, diabetes, known immunodeficiency, or a history of alcoholism/drug abuse within 2 years. Participants are also excluded if they have used CYP3A4/2C8 inhibitors within 14 days or inducers within 28 days prior to dosing. The study is actively enrolling. |
| This study, likely Phase 1, focuses on drug interactions of TAK-279 in healthy adults. Key exclusion criteria based on lab values include fasting glucose >125 mg/dL, estimated glomerular filtration rate (eGFR) <80 mL/min/1.73 m^2, or liver function tests (ALT, AST, ALP, total bilirubin) > ULN at screening. Participants must also have seated blood pressure between 90/40 and 140/90 mmHg and pulse rate between 40 and 99 bpm. The trial is currently recruiting. |
| This Phase 1 study investigates drug interactions of TAK-279 in healthy adults. Participants are excluded if they have donated blood within 56 days or plasma within 7 days prior to the first dosing. Additionally, individuals who have participated in another clinical study within 30 days prior to the first dosing are not eligible. The primary objective is to understand drug-drug interactions, and the study is actively recruiting. |
| |
| |
| This research study investigates the quality of life in patients with cutaneous lymphoma using the Skindex29. Patients are eligible if they have a presumed or confirmed diagnosis of cutaneous lymphoma. The study is observational, focusing on patient-reported outcomes, and requires participants' agreement. This active study aims to gather comprehensive quality of life data." |
| NCT04670874,What type of assessment tool is being utilized in the NCT04670874 study for cutaneous lymphoma patients?,"This research study is designed to evaluate the quality of life in patients diagnosed with cutaneous lymphoma. The primary assessment tool used is the Skindex29, a validated questionnaire for dermatological conditions. Participants are required to have a presumed or confirmed diagnosis of cutaneous lymphoma and agree to participate. This active observational study aims to understand the patient experience." |
| NCT01563874,What is the main scientific objective of the proteomic-based profiling study in lymphomas?,"This research study aims to analyze the histone and chromatin modifications, including the composition and modification of histone and non-histone chromosomal proteins, in lymphoid malignancies. The primary objective is proteomic-based profiling of lymphomas and lymphoid hyperplasia. It involves analyzing frozen biopsy material from patients with lymphoid malignancies or non-malignant lymphoid tissue. This translational research is currently active." |
| NCT01563874,What types of tissue samples are being collected for the proteomic analysis in the NCT01563874 study?,"This research study focuses on proteomic-based profiling of lymphomas and lymphoid hyperplasia. Tissue samples are collected from patients with lymphoid malignancies (solid tumors or circulating cells) and non-malignant lymphoid tissue, such as hyperplastic tonsils or lymph nodes. The primary objective is to analyze histone and chromatin modifications, requiring sufficient frozen biopsy material. This active study is crucial for understanding lymphoma biology." |
| NCT01563874,Are there any specific requirements regarding the quantity or type of biopsy material for inclusion in the lymphoma proteomic study?,This research study aims to perform proteomic-based profiling of lymphomas and lymphoid hyperplasia by analyzing histone and chromatin modifications. A critical inclusion criterion is the availability of sufficient frozen biopsy material from initial biopsies and/or biopsies at relapse of disease to obtain adequate tissue lysates for proteomic analyses. Samples from minors under 18 years old are excluded. This active study emphasizes high-quality tissue samples. |
| NCT01563874,"Can non-malignant lymphoid tissues be included in the proteomic profiling study, and if so, what types?","This research study focuses on proteomic-based profiling of lymphomas and lymphoid hyperplasia. Yes, non-malignant lymphoid tissue is appropriate for analysis, primarily including hyperplastic lymphoid tissue such as tonsils, or other hyperplastic and non-malignant lymph node samples showing proliferative responses or sinus histiocytosis. The primary objective is to compare these with malignant samples. This active study provides a crucial control group." |
| NCT07389616,"For which specific patient population with Peripheral T-Cell Lymphoma is the Cidabenamine plus Azacitidine trial designed, and what are the high-risk criteria for enrollment?","This clinical trial investigates Cidabenamine plus Azacitidine to prevent post-transplant progression in high-risk peripheral T-cell lymphoma (PTCL) patients. Eligible patients are aged 18-70 with a PTCL diagnosis (excluding hepatosplenic T-cell lymphoma) who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). High-risk criteria include stable disease (SD) at transplantation, relapse after autologous HSCT, or achieving at least Partial Response 1 (PR1). The study is currently recruiting." |
| NCT07389616,What are the key hematological and performance status requirements for patients to be eligible for the Cidabenamine plus Azacitidine trial in PTCL?,This clinical trial evaluates Cidabenamine plus Azacitidine for preventing post-transplant progression in high-risk peripheral T-cell lymphoma. Patients must have an ECOG performance status of 0 or 1. Hematological function must meet specific requirements: absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L and platelet count (PLT) ≥ 50 × 10⁹/L. The study is actively enrolling patients who have undergone allo-HSCT. |
| NCT07389616,Which pre-existing medical conditions or infections would exclude a patient with PTCL from participating in the Cidabenamine plus Azacitidine post-transplant progression prevention trial?,"This clinical trial aims to prevent post-transplant progression in high-risk peripheral T-cell lymphoma using Cidabenamine plus Azacitidine. Exclusion criteria include grade II or higher active acute Graft-versus-Host Disease (GVHD), moderate or more severe chronic GVHD, any unstable systemic disease (e.g., unstable angina, severe arrhythmia), active uncontrolled infection, known HIV infection, or active Hepatitis B/C requiring antiviral therapy. The study is currently recruiting." |
| NCT07389616,What is the primary goal of the NCT07389616 study involving Cidabenamine and Azacitidine in Peripheral T-Cell Lymphoma?,This clinical trial is designed to prevent post-transplant progression in high-risk peripheral T-cell lymphoma (PTCL) patients using a combination of Cidabenamine and Azacitidine. The study targets patients aged 18-70 who have undergone allogeneic hematopoietic stem cell transplantation and meet specific high-risk criteria. The primary objective is to evaluate the efficacy of this drug combination in preventing disease progression. This interventional study is currently active. |
| NCT00323076,What types of cancers are being investigated in the [18]F-FAZA PET imaging study?,"This imaging study utilizes [18]F-FAZA PET in patients with various cancers. The conditions being investigated include squamous cell carcinoma of the head and neck, non-small cell or small cell carcinoma of the lung, lymphoma, GBM (grade 3 or higher glioma), neuroendocrine tumors, and renal cell carcinoma. The primary objective is to evaluate the imaging capabilities of [18]F-FAZA. This study is currently active." |
| NCT00323076,Are there any specific tumor size requirements for lesions to be included in the [18]F-FAZA PET imaging study?,"This imaging study, likely Phase 1/2 for a novel tracer, uses [18]F-FAZA PET in patients with various cancers including renal cell carcinoma and neuroendocrine tumors. A key inclusion criterion is the presence of at least one lesion greater than 1 cm in diameter. The primary objective is to assess the imaging characteristics of the tracer. This study is currently active." |
| NCT00323076,What are the age and gender-specific eligibility criteria for participation in the [18]F-FAZA PET imaging study?,"This imaging study, likely Phase 1/2, involves [18]F-FAZA PET in patients with various cancers. Participants must be male or female and at least 16 years of age. For females of child-bearing potential, a negative pregnancy test is required if outside the window of 10 days since the first day of the last menstrual period. The study is currently active." |
| NCT00323076,What is the primary purpose of the NCT00323076 study involving [18]F-FAZA PET imaging?,"This imaging study, likely Phase 1/2, is designed to evaluate [18]F-FAZA PET in patients with various cancers, including head and neck, lung, renal cell, brain, lymphoma, and neuroendocrine tumors. The primary objective is to assess the utility of this imaging agent in these specific cancer types. Patients must have at least one lesion greater than 1 cm in diameter. This study is currently active." |
| NCT00345189,"What are the specific hematological, hepatic, and renal function requirements for patients with advanced solid tumors to be eligible for the oral CNF2024 (BIIB021) study?","This study, likely Phase 1 or early Phase 2, investigates oral CNF2024 (BIIB021) in patients with advanced solid tumors who have failed standard therapies. Eligibility requires an absolute neutrophil count >1500 cells/mm3, platelet count >100,000 cells/mm3, and hemoglobin >=9 gm/L. Hepatic function must show bilirubin <1.5 X ULN and ALT/AST <2.5 X ULN (or <5.0 X ULN with liver metastases), while renal function requires serum creatinine <2.0 mg/dL or creatinine clearance >60 mL/min. The study is currently active." |
| NCT00345189,Which prior treatments or concurrent medical conditions would exclude a patient with advanced solid tumors from participating in the CNF2024 (BIIB021) trial?,"This study, likely Phase 1 or early Phase 2, evaluates oral CNF2024 (BIIB021) in advanced solid tumors. Exclusion criteria include radiotherapy or chemotherapy within the previous 28 days, participation in another investigational drug study within 28 days, or active infection requiring intravenous antibiotics. Patients with active HIV, viral hepatitis, or concurrent severe uncontrolled medical diseases like diabetes (at investigator's discretion) are also excluded. The study is currently active. |
| This study, likely Phase 1 or early Phase 2, is investigating the oral drug CNF2024 (BIIB021) in patients with advanced solid tumors, including lymphoma, who have failed standard therapies or for whom effective therapy is unavailable. The primary objective is to evaluate the safety and efficacy of this intervention. Participants must be at least 18 years old with an Eastern Cooperative Oncology Group (ECOG) performance status of <=2. The study is currently active. |
| This study, likely Phase 1 or early Phase 2, evaluates oral CNF2024 (BIIB021) in advanced solid tumors. Patients must have a normal electrocardiogram (ECG) with QTc <=450 msec for men and <=470 msec for women. Normal plasma cortisol and adrenocorticotropic hormone (ACTH) levels are required, and adrenal dysfunction greater than Grade 2 is an exclusion criterion. The study is currently active. |
| This clinical trial, likely Phase 2, investigates Daratumumab and Dose-Adjusted EPOCH in plasmablastic lymphoma. Participants must have histologically and immunophenotypically documented plasmablastic lymphoma. Eligibility requires Ann Arbor Stage II-IV disease, or Stage I disease with elevated lactate dehydrogenase (LDH) or a bulky tumor (>7.5 cm). The primary objective is to evaluate this combination therapy, and the study is currently recruiting. |
| This clinical trial, likely Phase 2, evaluates Daratumumab and Dose-Adjusted EPOCH in plasmablastic lymphoma. Known HIV status is required, with a limit of 7 HIV-negative patients allowed; subsequent enrollment is restricted to HIV-positive patients. HIV-positive participants must have a CD4 count >=100 cells/mL, no history of AIDS-defining opportunistic infection within the past year, and be on or agree to start effective highly active antiretroviral therapy (HAART). The study is currently recruiting. |
| This clinical trial, likely Phase 2, combines Daratumumab and Dose-Adjusted EPOCH for plasmablastic lymphoma. Participants must have adequate cardiac function, defined as an ejection fraction (EF) on echocardiogram (ECHO) or multigated acquisition scan (MUGA) that is at or above 45%. Renal function requires creatinine <=1.5 x institutional upper limit of normal (ULN) or a glomerular filtration rate (GFR) >=45 mL/min/1.73 m^2. The study is currently recruiting. |
| This clinical trial, likely Phase 2, investigates Daratumumab and Dose-Adjusted EPOCH in plasmablastic lymphoma. Exclusion criteria include prior cytotoxic chemotherapy or radiotherapy for this lymphoma (with specific exceptions), prior exposure to daratumumab, or being on strong CYP3A4 inhibitors. Patients with peripheral neuropathy grade >=3, expected survival <2 months, known brain metastases, or active Hepatitis B/C are also ineligible. The study is currently recruiting. |
| |
| This Phase II/III Lung-MAP sub-study (S1400I) investigates Nivolumab with or without Ipilimumab as second-line therapy for recurrent Stage IV squamous cell lung cancer. Patients must not have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibodies, or any other drug targeting T-cell costimulation or immune checkpoint pathways. Systemic corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications are also prohibited within 14 days prior to registration. The study is currently active. |
| This Phase II/III Lung-MAP sub-study (S1400I) evaluates Nivolumab with or without Ipilimumab for recurrent Stage IV squamous cell lung cancer. Patients must not have an active, known, or suspected autoimmune disease, though exceptions include vitiligo, type I diabetes, hypothyroidism (requiring hormone replacement), and psoriasis not requiring systemic treatment. Patients with known HIV or active Hepatitis B are excluded, but those with a positive Hepatitis C antibody and a negative viral load are permitted. The study is currently active. |
| This Phase II/III Lung-MAP sub-study (S1400I) investigates Nivolumab with or without Ipilimumab as second-line therapy for recurrent Stage IV squamous cell lung cancer. Patients must not have any Grade III/IV cardiac disease as defined by the New York Heart Association Criteria, unstable angina pectoris, or myocardial infarction within 6 months. Serious uncontrolled cardiac arrhythmia is also an exclusion criterion. The study is currently active. |
| This clinical trial, likely Phase 2/3, evaluates Bendamustine and Rituximab for previously untreated extranodal MALT lymphoma. Participants must have a histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type, arisen at any extranodal site, and be of any Ann Arbor stage (I-IV). Patients must have de novo disease, with specific allowances for recurrent cutaneous lymphoma after local therapy or H. pylori-positive gastric lymphoma that failed antibiotic therapy. The study is currently active. |
| This clinical trial, likely Phase 2/3, investigates Bendamustine and Rituximab in previously untreated extranodal MALT lymphoma. Eligible patients must be aged between 18 and 85 years. They must also have an ECOG performance status of 0-2 and a life expectancy of at least 1 year. The primary objective is to assess the efficacy of the combination therapy. The study is currently active. |
| Which organ function parameters are critical for eligibility in the Bendamustine and Rituximab trial for MALT lymphoma, and what are the acceptable limits?This clinical trial, likely Phase 2/3, evaluates Bendamustine and Rituximab for previously untreated extranodal MALT lymphoma. Patients must not have major impairment of renal function (serum creatinine > 2.5 x ULN) or liver function (ASAT/ALAT <2.5 x ULN, total bilirubin <2.5x ULN), unless these impairments are due to lymphoma involvement. Bone marrow function also has specific limits (WBC <3.0x10^9/L, ANC <1.5x10^9/L, PLT <100x10^9/L), again with exceptions for lymphoma involvement. The study is currently active. |
| This clinical trial, likely Phase 2/3, investigates Bendamustine and Rituximab for previously untreated extranodal MALT lymphoma. Patients with active HBV and/or HCV infection or known HIV infection are excluded. A prior diagnosis of neoplasm within 5 years is also an exclusion criterion, with the exception of cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer. The study is currently active. |
| This clinical trial, likely Phase 2, evaluates L-asparaginase monotherapy as salvage treatment for patients with NK/T cell lymphoma. Participants must have a histologically confirmed diagnosis of NK/T cell lymphoma with progressive or recurrent disease. The primary objective is to assess the efficacy of L-asparaginase in this setting. The study is currently active. |
| This clinical trial, likely Phase 2, investigates L-asparaginase monotherapy as salvage treatment for NK/T cell lymphoma. Eligible patients must be between 18 and 75 years old. They are also required to have an ECOG performance status of 0-2 and a life expectancy of more than 3 months. The primary objective is to evaluate the drug's effectiveness. The study is currently active." |
| NCT00854425,What are the required laboratory values for patients to be included in the L-asparaginase monotherapy trial for NK/T cell lymphoma?,"This clinical trial, likely Phase 2, evaluates L-asparaginase monotherapy as salvage treatment for NK/T cell lymphoma. Patients must have normal laboratory values, including hemoglobin >80 g/dl, neutrophil >2×10^9/L, and platelet >100×10^9/L. Additionally, serum creatinine must be <1.5×ULN, serum bilirubin <1.5×ULN, and ALT and AST <2.5×ULN. The study is currently active." |
| NCT00854425,Which conditions would exclude a patient with NK/T cell lymphoma from receiving L-asparaginase monotherapy in this salvage treatment trial?,"This clinical trial, likely Phase 2, investigates L-asparaginase monotherapy as salvage treatment for NK/T cell lymphoma. Exclusion criteria include pregnancy or lactation, serious uncontrolled diseases, intercurrent infection, or evidence of CNS metastasis. A history of other malignancies is also exclusionary, with the exception of cured basal cell carcinoma of the skin and carcinoma in-situ of the uterine cervix. The study is currently active." |
| |
